Obsidian Therapeutics Completes Three-Way Merger, Raises $350 Million

What happened

Obsidian Therapeutics, Inc. completed a two-step merger on August 3, 2026, according to a Form 8-K filed the same day. The company, which was named Gazelle Parent, Inc. until July 31, 2026, is a clinical-stage biopharmaceutical company developing engineered tumor-infiltrating lymphocyte cell therapies.

Under the merger agreement signed April 14, 2026, two mergers closed on the same day: Obsidian Therapeutics Sub, Inc. (the former Obsidian Therapeutics, Inc., or "Legacy Obsidian") merged into the parent company, and then Galera Therapeutics, Inc. ("Legacy Galera") merged into the parent company. Both former companies became wholly owned subsidiaries of the combined company.

The filing states that approximately 61,727,211 shares of common stock were outstanding immediately after the mergers. Legacy Obsidian securityholders received about 31,831,595 shares, Legacy Galera securityholders received about 730,057 shares, and investors in a concurrent financing received about 29,165,559 shares. Following the mergers, the filing says Legacy Obsidian securityholders owned about 51.6% of the combined company, Legacy Galera securityholders about 1.2%, and the financing investors about 47.2%.

The financing and other agreements

Concurrent with the merger, investors bought $350.0 million of Legacy Galera's Series C Non-Voting Convertible Preferred Stock. The filing calls this the "Concurrent PIPE Financing." That preferred stock converted into common stock before the Galera merger closed, and those shares were exchanged for parent company common stock.

The filing also describes a registration rights agreement requiring Obsidian to file a shelf registration statement covering resale of the investors' shares within 30 days of closing. A contingent value right agreement gives former Galera stockholders one CVR per share, tied to 80% of future net proceeds from a specified "Legacy Product" over five years and 95% of proceeds from a "Supportive-Care Product Divestiture" over ten years. The filing states there is no assurance any CVR holder will receive a payment. The CVRs carry no voting or dividend rights and are not registered with the SEC.

Lock-up agreements restrict transfers by certain Legacy Obsidian stockholders, directors, and executive officers for 180 days after closing (excluding shares bought in the PIPE financing). Obsidian also entered indemnification agreements with each director and executive officer of the former parent company. The filing says the mergers are intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.

What this means

A Form 8-K is a current report that a public company must file with the SEC when certain material events occur between quarterly reports. The item numbers in the header tell readers what categories of events the filing covers: here, Item 2.01 signals a completed acquisition or disposition of assets, and Item 1.01 signals entry into a material agreement.

A PIPE financing (private investment in public equity) is a way for a company to raise money by selling shares or convertible securities directly to institutional or accredited investors, rather than through a public offering. In this case the financing was structured through preferred stock that converted into common stock as part of the merger, so the investors ended up holding roughly 47% of the combined company. The filing does not state the price per share or the terms of the preferred stock.

A contingent value right (CVR) is a contractual right to receive a future payment if a specified event occurs. Here, the events are net proceeds from developing, selling, or licensing a particular product and from divesting a supportive-care product. CVRs are a common way to bridge a price gap in an acquisition when the two sides disagree about what a pipeline asset is worth. They are not stock: they carry no vote, no dividend, and no ownership stake; they cannot be traded except in limited cases; and they pay nothing if the underlying milestones do not happen.

The filing does not explain why Galera and Obsidian chose to merge or describe the combined company's future plans or financial condition. Those details are not in this document.